Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.5% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) is a company specializing in diabetes management technologies, with a focus on automated insulin delivery systems. Today, the stock of TNDM experienced a significant bearish movement in the market.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 5.5% on Apr 28, 2026 14:45

• The FDA clearance for Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy complicated by type 1 diabetes, while positive news, might have raised concerns about potential competition in the market leading to a bearish sentiment.
• Despite positive analyst upgrades from Truist Securities and Piper Sandler on Tandem's new pharmacy distributor model and strategy, the market may have reacted negatively due to profit-taking by investors after recent gains.
• Tandem Diabetes Care's strategic transformation initiatives outlined at the TD Cowen 46th Annual Health Care Conference could be seen as promising for the company's future growth, but the market may have interpreted them as long-term investments impacting short-term profitability, contributing to the bearish movement.
• Overall, the bearish movement in TNDM stock today could be a result of a combination of profit-taking, market competition concerns, and short-term impact of strategic transformations on profitability.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

FDA clears Control-IQ+AID technology for use in pregnancy complicated by type 1 diabetes

The FDA has expanded clearance for Tandem Diabetes Care's Control-IQ+ automated insulin delivery (AID) technology for use in pregnancies complicated by type 1 diabetes. This makes it the first commercially available AID system in the U.S. cleared for this use, based on data from the CIRCUIT trial which showed improved time in the pregnancy-specific glucose range. Tandem Diabetes Care plans to conduct training and webinars for healthcare providers on this expanded indication.

https://www.contemporaryobgyn.net/view/fda-clears-control-iq-automated-insulin-delivery-technology-for-use-in-pregnancy

Tandem Diabetes Care’s Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes

Tandem Diabetes Care has announced that its Control-IQ+ automated insulin delivery (AID) technology has received FDA clearance for use in pregnancy in individuals with type 1 diabetes. This makes Control-IQ+ the first and only commercially available AID technology cleared for pregnancy in the U.S., based on the positive results of the CIRCUIT trial published in JAMA, which showed improved glycemic control in pregnant participants. The technology is available on both the t:slim X2 and Tandem Mobi insulin delivery systems.

https://www.businesswire.com/news/home/20260427815489/en/Tandem-Diabetes-Cares-Control-IQ-Automated-Insulin-Delivery-Technology-Now-FDA-Cleared-for-Pregnancy-in-Type-1-Diabetes

Tandem gains as Truist becomes latest to upgrade on new pharmacy model

Tandem Diabetes Care (TNDM) stock gained after Truist Securities upgraded the company's rating from Hold to Buy, citing optimism about its new pharmacy distributor model. The new model, launched at the beginning of the year, aims to increase access to Tandem's t:slim X2 pump for patients. Truist analysts believe this strategy will improve sales and market penetration, despite initial "birthing pains."

https://www.msn.com/en-us/health/other/tandem-gains-as-truist-becomes-latest-to-upgrade-on-new-pharmacy-model/ar-AA1YZwB3?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c

Tandem rises as Piper Sandler upgrades on pharmacy strategy

Piper Sandler upgraded Tandem Diabetes Care to Overweight from Neutral, citing the company's new pharmacy strategy as a significant growth driver. Tandem's shares rose following the analyst upgrade. This strategic shift is expected to improve access and reduce costs for patients.

https://www.msn.com/en-us/health/other/tandem-rises-as-piper-sandler-upgrades-on-pharmacy-strategy/ar-AA1YPl5x?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-t

Tandem Diabetes Care (TNDM) TD Cowen 46th Annual Health Care Conference Summary

Tandem Diabetes Care (TNDM) outlined its strategic transformation at the TD Cowen 46th Annual Health Care Conference, focusing on monetizing its sales force, launching new products, and expanding market access through the pharmacy channel. Key initiatives include a "PAYGO" model for pumps and supplies, the upcoming launch of Mobi Tubeless and a fully closed-loop algorithm, and an expanded sales force. These strategies aim to drive revenue, profitability, and pump shipment growth while reducing patient and physician friction.

https://quartr.com/events/tandem-diabetes-care-tndm-td-cowen-46th-annual-health-care-conference_3Pa7aCl3

Trending Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.1% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Down 8.4% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 5.2% Today

Centene Corporation ($CNC) Stock Forecast: Up 12.8% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Down 5.2% Today

Spotify Technology S.A. ($SPOT) Stock Forecast: Down 15.5% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.1% Today

Coca-Cola Company (The) ($KO) Stock Forecast: Up 5.2% Today

Newell Brands Inc. ($NWL) Stock Forecast: Down 5.0% Today

UnitedHealth Group Incorporated (DE) ($UNH) Stock Forecast: Up 5.1% Today

Tandem Diabetes Care, Inc. Price History

21.03.2026 - TNDM Stock was down 5.2%

• Tandem Diabetes Care (TNDM) stock saw a decrease, despite TD Cowen boosting its price target to $28 and maintaining a Buy rating. The decline could be linked to investors taking profits after a period of price appreciation.
• The Chief Operating Officer of the company exercised restricted stock units (RSUs), with some shares held back for taxes. This action may have added selling pressure on the stock as more shares became available in the market.
• Although there was excitement surrounding the upcoming launch of the Mobi Tubeless product and a new pay-as-you-go program, these factors might not have been enough to counterbalance the short-term selling pressures that led to the observed decrease in stock value.

19.02.2026 - TNDM Stock was up 5.6%

• Despite reporting a Q4 loss, Tandem Diabetes Care exceeded revenue expectations, showcasing strong growth in its top line.
• The exercise of Restricted Stock Units by company executives and insiders selling shares may have initially caused some downward pressure on the stock price.
• A stock upgrade by Piper Sandler and a positive market outlook contributed to the bullish movement, reflecting investor confidence in the company's future prospects.
• The detailed financial overview and competitor comparison provided insights into Tandem Diabetes Care's revenue sources and financial health, potentially reassuring investors and contributing to the positive market sentiment.

28.03.2026 - TNDM Stock was down 5.5%

• The FDA clearance for Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy complicated by type 1 diabetes, while positive news, might have raised concerns about potential competition in the market leading to a bearish sentiment.
• Despite positive analyst upgrades from Truist Securities and Piper Sandler on Tandem's new pharmacy distributor model and strategy, the market may have reacted negatively due to profit-taking by investors after recent gains.
• Tandem Diabetes Care's strategic transformation initiatives outlined at the TD Cowen 46th Annual Health Care Conference could be seen as promising for the company's future growth, but the market may have interpreted them as long-term investments impacting short-term profitability, contributing to the bearish movement.
• Overall, the bearish movement in TNDM stock today could be a result of a combination of profit-taking, market competition concerns, and short-term impact of strategic transformations on profitability.

30.02.2026 - TNDM Stock was down 5.4%

• An amended Schedule 13G/A filing by The Vanguard Group, indicating 0 shares beneficially owned, could have triggered uncertainty among investors.
• An ongoing investigation by the Portnoy Law Firm regarding potential securities fraud linked to malfunctions in Tandem's insulin pumps likely impacted the company's product reliability and financial transparency, resulting in a stock price decline.
• Despite exceeding Q4 earnings estimates, a neutral recommendation from Mizuho and a consensus "Hold" rating from analysts may have contributed to the subdued sentiment surrounding Tandem Diabetes Care, aligning with the bearish market movement.
• The combination of the investigation, neutral recommendations, and the lack of clear bullish sentiments likely intensified selling pressure on TNDM shares, leading to the observable significant bearish movement.

14.03.2026 - TNDM Stock was up 6.0%

• The surge in TNDM stock price could be attributed to the company being perceived as undervalued, with a GF Score of 74 indicating above-average potential for long-term returns.
• Maintaining a "Hold" rating and a target price of $22 might have provided investors with confidence in the current valuation of the stock.
• Positive sentiment from an AI analysis suggesting specific trading strategies and key support levels could have attracted more investors to TNDM.
• The overall bullish trend in the diabetes care market, with projected growth and technological advancements, might have positively impacted TNDM's stock price as it positions itself as a key player in the industry.

08.03.2026 - TNDM Stock was up 5.6%

• The bullish movement in Tandem Diabetes Care's stock today could be attributed to the company's request for shareholder approval for an increase in shares to its Long-Term Incentive Plan, signaling confidence in its future growth prospects.
• The projected growth in the Smart Insulin Management Devices Market, where Tandem Diabetes Care is a key player, could have also positively impacted investor sentiment and contributed to the stock's rise.
• Despite a reduction in stake by a notable financial institution, the overall market seems optimistic about Tandem Diabetes Care's performance, especially with the upcoming announcement of its first-quarter 2026 financial results, which investors are eagerly anticipating for insights into the company's trajectory.

13.03.2026 - TNDM Stock was up 5.5%

• TNDM stock started positively with a 5.69% gain, surpassing the S&P 500 performance.
• The optimistic outlook is supported by AI models suggesting favorable short-term sentiment and specific trading recommendations for large investors.
• In spite of a reduced price target by Goldman Sachs, TNDM stock remained strong, demonstrating robust confidence from investors in the company's potential for growth.
• Anticipated market expansion in diabetes care market by 2030, along with TNDM's innovative product range, likely influenced the market positively as investors foresee rising demand for diabetes care solutions.

24.02.2026 - TNDM Stock was down 6.4%

• Despite recent positive developments, Tandem Diabetes Care (TNDM) saw a decrease in stock value.
• Investors may have been discouraged by the company's lack of profitability despite exceeding earnings and revenue projections, prompting some to realize profits.
• While analysts praised TNDM's pay-as-you-go pharmacy model, this alone may not have calmed market worries or profit expectations.
• The decline in stock value could be influenced by broader market trends or factors specific to Tandem Diabetes Care's industry performance.

27.02.2026 - TNDM Stock was down 6.9%

• Tandem Diabetes Care, Inc. experienced a bearish movement due to a significant 19.9% stock price drop following the disclosure of a malfunction in its insulin pumps.
• An investigation regarding potential securities fraud added further uncertainty and negative sentiment towards the company.
• The malfunction in the insulin pumps, which could lead to serious health complications for users, likely raised concerns among investors about the company's product safety and reliability.
• The market reacted strongly to the news, reflecting the importance of transparency and reliability in the healthcare technology sector.

07.03.2026 - TNDM Stock was up 6.2%

• Significant divestment of Tandem Diabetes Care shares by JPMorgan Chase & Co. initially raised investor concerns, but the market sentiment later turned positive.
• Despite Tandem Diabetes Care's ongoing lack of profitability, the stock witnessed a bullish trend leading up to the upcoming Q1 2026 financial results announcement.
• A mix of analyst opinions, resulting in a "Hold" consensus rating, and upgrades from some firms, likely influenced the positive investor sentiment as the company's potential was reassessed.
• Market enthusiasm and confidence in Tandem Diabetes Care's future performance, bolstered by beating earnings estimates for the quarter, drove the stock to a significant bullish movement.

07.03.2026 - TNDM Stock was down 5.8%

• The Smart Insulin Management Devices Market is projected to grow substantially by 2033, indicating a positive industry outlook. However, Tandem Diabetes Care's stock experienced a bearish trend.
• A reduction of 36.1% in Tandem Diabetes Care's stake by JPMorgan Chase & Co. could have contributed to the negative sentiment surrounding the stock.
• Despite beating earnings estimates, Tandem Diabetes Care remains unprofitable, leading to mixed analyst sentiment and a "Hold" consensus rating.
• The upcoming announcement of Tandem Diabetes Care's Q1 2026 results may have investors cautious, waiting for insights into the company's performance and future prospects before making investment decisions.

16.03.2026 - TNDM Stock was down 6.1%

• TNDM shares rose by 4.8% to $20.10, despite being undervalued, potentially prompting profit-taking by investors and contributing to the bearish trend.
• Mizuho Securities has maintained a "Hold" rating with a target price of $22, suggesting a neutral outlook that may not be driving significant positive momentum for the stock.
• Institutional trading strategies utilizing AI models could have resulted in selling pressure if recommended short positions were achieved.
• Anticipated growth in the diabetes care market until 2030 may have redirected investor attention towards other industry leaders, negatively impacting TNDM's stock performance in the short term.